NDAORALTABLET
Approved
Sep 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
6/8 — Strong
COREG (carvedilol) by Viatris (2) is adrenergic alpha-antagonists [moa]. Approved for hypertension, heart failure, left ventricular dysfunction. First approved in 1995.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COREG (carvedilol) is an oral alpha-adrenergic blocker approved in 1995 for hypertension, heart failure, and left ventricular dysfunction. It works by blocking alpha-adrenergic receptors to reduce blood pressure and improve cardiac function. The drug is indicated across 14 conditions spanning cardiovascular, metabolic, and oncologic domains.
$0.587MPart D
LOE ApproachingCOREG is in late-stage maturity with minimal Medicare Part D spending and approaching loss of exclusivity, signaling a defensive, cost-focused commercial team.
Mechanism of Action
Adrenergic alpha-Antagonists
Pharmacologic Class:
alpha-Adrenergic Blocker
Indications (3)
Worked on COREG at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.